Haematology Flashcards

(167 cards)

1
Q

Malaria

A

a parasitic infection caused by protozoa of the genus plasmodium, this infection is almost exclusively sen in tropics & subtropics

Notifiable disease in the UK

NB consider malaria in every febrile travel returning from a malaria endemic area in the last year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Protective factors for malaria

A

sickle cell trait
G6PD deficiency
HLA-B53

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Species of malaria

A

Plasmodium falciparum

  • commonest type
  • most severe kind

non falciparum (plasmodium vivax/ovale/malarine)

  • plasmodium vivax is most common
  • vivax is usually benign
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Presentation of malaria

A

fever

  • often recurring
  • cyclical, occurring every 48-72h

chills, rigors, headache, cough, myalgia, GI upset
jaundice
hepato/splenomegaly

Severe disease (usually P. falciparum)

  • impaired consciousness
  • SOB
  • bleeding
  • fits
  • AKI, ARDS, anaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Investigations for malaria

A

Blood smears with Giemsa stain

  • gold standard
  • presence of parasites within RBCs

FBC

  • ↓Hb
  • thrombocytopenia
  • ↑ reticulocytes

Rapid diagnostic tests (RDIs)
-detect parasite antigens

LFTs
-often abnormal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Management of malaria

A

Falciparum:

  • Artemisinin-based combination therapy (ART) or PO quinine if uncomplicated
  • IV quinine in severe disease

Non-falciparum malaria:

  • 1st line = chloroquine
  • 2nd line = ART (1st line if chloroquine resistance)
  • primaquine (as relapse prevention, destroys liver hypnozoites)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Prevention of malaria

A

reduced chance of being bitten

  • misquito nets
  • mosquito spray

Chemoprophylaxis

  • start 1 week befogging entering malarious area
  • chloroquine, proguanil, mefloquine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hodgkin’s lymphoma

A

malignant tumour of the lymphatic system characterised histologically by the presence of Reed-Sternberg cells (multinucleate giant cells)

Bi-modal age distribution

  • peak age 20-34yrs
  • 2nd peak >70yrs

classical Hodgkin’s lymphoma (most common), especially nodular sclerosing kind

NB lymphocyte deplete kind is rare & carries worst prognosis

Risk factors include immunodeficiency, EBV infection & autoimmune disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hodgkin’s lymphoma characteristic histological feature

A

Reed-Sternberg cells (multinucleate giant cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Presentation of Hodgkin’s lymphoma

A

painless non tender asymmetrical lymphadenopathy

  • most frequently affects cervical nodes
  • may present as mediastinal mass

B symptoms

  • weight loss, fever, night sweats
  • imply poor prognosis

alcohol induced pain at sites of nodal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Investigations for Hodgkin’s lymphoma

A

FBC

  • ↑/↓ WCC
  • ↓Hb
  • eosinophilia

Lymph node biopsy

  • Reed-Sternberg cells
  • Hodgkins cells

CXR

  • mediastinal mass
  • mediastinal lymphadenopathy

ESR (↑), LDH (↑)

CT, Gallium scan, PET-CT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Management of Hodgkin’s lymphoma

A

chemo+radiotherapy
-ABVD or BEACOPP regimes

autologous stem cell transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Non-Hodgkin’s lymphoma

A

a heterogenous group of malignancies of the lymphoid system, ~5x more common than Hodgkin’s lymphoma

usually seen in >50y/o pts

Subtypes

  • B-cell lymphomas (~85%)
  • T-cell lymphomas (~15%)

Risk factors include Caucasian origin, EBC infection, FH of lymphoma, immunodeficiency, autoimmune disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Presentation of Non-Hodgkin’s lymphoma

A

painless lymphadenopathy

  • non tender
  • rubbery
  • asymmetrical

constitutional/B-symptoms
-fever, weight loss, night sweats, lethargy

splenomegaly, hepatomegaly

Extra-nodal disease (more common than in Hodgkins)
-early satiety, GI bleeding, headache, skin lesions, pruritus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Investigations for Non-Hodgkin’s lymphoma

A

excision node biopsy
-investigation of choice

CT chest/abdo/pelvis

FBC (↓Hb), ESR (↑), LDH (↑)
PET-CT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Management of Non-Hodgkin’s lymphoma

A

depends on subtype

generally watch & wait (if low grade), chemo or radiotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Burkitt’s lymphoma

A

high grade non-hodgkins lymphoma, that is rapidly growing & aggressive

usually seen in children, and is strongly associated with EBV infection

characterised by starry-sky appearance on biopsy (lymphocyte sheets interspersed with macrophages containing dead apoptotic tumour cells)

managed with chemo

Strongly associated with tumour lysis syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Acute lymphoblastic leukaemia (ALL)

A

a malignant clonal disease that develops when lymphoid progenitor cells undergo uncontrolled proliferation

most common cancer in children with peak incidence at 2-5yrs
-~80% of leukemias in children)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Presentation of Acute lymphoblastic leukaemia (ALL)

A

sudden onset & rapid progression
fatigue dizziness, palpations, pallor, weakness
bone & joint pain
headache, neck stiffness
fever without obvious infection
bruising, epistaxis, petechiae, ecchymosis
LUQ fullness, early satiety (due to splenomegaly)
testicular enlargement
lymphadenopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Investigations for Acute lymphoblastic leukaemia (ALL)

A

FBC

  • ↓ Hb
  • ↓ platelets
  • ↓ neutrophils
  • ↓/↑WCC

Blood smear
-leukaemic lymphoblasts

Bone marrow aspiration &biopsy
-≥20% blast cells

clotting (may show DIC), LDH (↑), uric acid (↑)
LFTs, U&Es,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Management of Acute lymphoblastic leukaemia (ALL)

A

Induction (to restore normal haematopoesis)
-corticosteroids + vincristine/cyclophosphamide/doxorubicin

Maintenance
-mercaptopurine + methotrexate

CNS prophylaxis
-intrathecal methotrexate

Stem cell transplant

NB relapses after treatment have very poor prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Acute myeloid leukaemia (AML)

A

the malignant clinical expansion of myeloid blasts in the bone marrow, peripheral blood or extra medullary tissue

may be primary disease or secondary transformation of other lymphoproliferative disorders

Most common acute leukaemia in adults usually seen age 65yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Risk factors for Acute myeloid leukaemia (AML)

A

aplastic anaemia
myelofibrosis
paroxysmal nocturnal haemoglobulinaemia
polycythaemia rubera vera

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Presentation of Acute myeloid leukaemia (AML)

A
anaemia (pallor, fatigue, weakness)
fever
petechiae
purpura
ecchymosis 
epistaxis
frequent infections 
hepatosplenomegaly 
leukaemia cutis (nodular skin lesions, gray-blue/purple)
gingival hypertrophy
gingivitis 
bleeding gums
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Investigations for Acute myeloid leukaemia (AML)
FBC - ↓ Hb - ↓ platelets - ↓ neutrophils clotting - DIC common - ↑PT, ↑aPTT, ↓fibrinogen LDH (↑) Bone marrow biopsy -≥20% blast cells LFTs, U&Es, blood film/smear
26
Management of Acute myeloid leukaemia (AML)
induction -cytarabine + daunorubicin consolidation -cytarabine / daunorubicin / mitoxantrone Stem cell transplant
27
Acute promyelotic anaemia (APL)
presents younger than other AMLs (~25y/o) often has DIC/thrombocytopenia at presentation has Auer-rods on histology treated with arsenic trioxide (ATO) or all-trans relinoic acid (ATRA)
28
Epidemiology of leukaemias
ALL = most common leukaemia in children CLL = most common leukaemia in adults -often has lymphadenopathy AML = most common acute leukaemia in adults CML= only ~15% of adult leukaemias - rarely has lymphadenopathy - associated with Philadelphia chromosome
29
Chronic lymphocytic anaemia (CLL)
malignant monoclonal expansion of B lymphocytes with accumulation of abnormal lymphocytes in blood / bone marrow / spleen / lymphnodes / liver most common leukaemia in adults, usually diagnosed ~70y/o
30
Presentation of Chronic lymphocytic anaemia (CLL)
variable presentation with insidious onset, may be symptomatic & incidentally found on blood test ``` symmetrically enlarged painless lymph nodes (NB CML rarely has lymphadenopathy) susceptibility to infection anorexia, weight loss hepatosplenomegaly, abdo discomfort brusing, petichae ```
31
Investigations for Chronic lymphocytic anaemia (CLL)
FBC - ↓ Hb - ↑↑ WCC - ↓ platelets Blood film -smear cells & smudge cells Immunophenotyping -key investigations Bone marrow aspirate / lymph node biopsy T53 gene test -done before treatment
32
Management of Chronic lymphocytic anaemia (CLL)
chemotherapy stem cell transplant if CD20 +ve -rituximab TP53 targeted therapy -ibrutinib
33
Chronic myeloid anaemia (CML)
a myeloproliferative disorder of pluripotent haemopoietic stem cells affecting one or all cell lines usually seen in adults age 60-65 yrs associated with Philadelphia chromosome in ~95% of pts
34
Presentation of Chronic myeloid anaemia (CML)
often asymptomatic & incidentally found on blood test, otherwise symptoms have insidious onset ``` fatigue, night sweats, weight loss abdo fullness, abdo distension LUQ pain splenomegaly & hepatomegaly easy bruising ``` NB CML only rarely has enlarged lymph nodes, but they are common in CLL = key differentiating factor
35
Investigations for Chronic myeloid anaemia (CML)
FBC - ↓ Hb - ↑ WCC (>100x10^9/L) - ↓/↑ platelets Blood film - all stages of maturation seen - looks like bone marrow aspire LDH (↑) leukocyte alkaline phosphate (↓) bone marrow aspirate & biopsy cytogenetics Fluorescent in situ hybridisation (FISH) quantitive reverse transcriptase PCR
36
Myeloma/multiple myeloma
a plasma cell dyscrasia characterised by terminally differentiated plasma cells, infiltration of the bone marrow by plasma cells and presence of a monoclonal immunoglobulin in the serum and/or urine classified by immunoglobulin type (IgG most common) 2nd most common haematological malignancy median age of presentation is 70yrs
37
Epidemiology of Myeloma/multiple myeloma
classified by immunoglobulin type -IgG most common type 2nd most common haematological malignancy median age of presentation is 70yrs
38
Epidemiology of Myeloma/multiple myeloma
classified by immunoglobulin type -IgG most common type 2nd most common haematological malignancy median age of presentation is 70yrs more common in men & afro-carribbeans
39
Presentation of Myeloma/multiple myeloma
bone pain -particularly back pain pathological fractures lethargy, anorexia, night sweats, weight loss ↑ Ca2+ (constipation, nausea, confusion) dehydration, thirst, pallor easy bruising / bleeding ↑susceptibility to infection & repeated infections
40
Presentation of Myeloma/multiple myeloma
bone pain -particularly back pain pathological fractures lethargy, anorexia, night sweats, weight loss ↑ Ca2+ (constipation, nausea, confusion) Renal damage (dehydration, thirst, pallor) easy bruising / bleeding ↑susceptibility to infection & repeated infections
41
Investigations for Myeloma/multiple myeloma
FBC - ↓ Hb - ↓ platelets U&Es - ↑ urea - ↑ creatinine serum / urine electrophoresis - ↑ monoclonal IgA / IgG - Bence-Joyce proteins in urine Bone marrow aspiration & biopsy -monoclonal plasma cell infiltration X-ray - rain drop skill - randomly placed dark spots due to bone lysis Ca2+ (↑) Whole body MRI
42
Diagnostic criteria for Myeloma/multiple myeloma
Symptomatic multiple myeloma is defined at diagnosis by the presence of all 3 of the following: - Monoclonal plasma cells in the bone marrow >10% - Monoclonal protein within serum / urine (as determined by electrophoresis) - Evidence of end-organ damage e.g. hypercalcaemia, elevated creatinine, anaemia or lytic bone lesions/fractures
43
Management of Myeloma/multiple myeloma
currently deemed incurable elderly pts/not suitable for transplant -Thalidomide + an Alkylating agent + Dexamethasone suitable for transplant - Bortezomib + dexamthasone - followed by stem cell transplant NB pts should be mounted every 3 months with blood tests & electrophoresis
44
Polycythaemia
refers to an increased number of Red blood cells in the body
45
Aetiology of Polycythaemia
Relative causes: -dehydration, stress (gaissbock syndrome) Primary: -polycythaemia vera Secondary - COPD - high altitude - OSA - uterine fibroids (cause ↑ EPO)
46
Polycythaemia vera
myeloproliferative disorder characterised by erythropoietic independent rise in erythrocyte & platelets count associated with a mutation in the JAK2 gene
47
Presentation of Polycythaemia vera
maybe be asymptomatic or incidentally found on blood tests hyper viscosity syndrome -mucosal bleeding, visual changes, neurological symptoms (dizziness, headache, tinnitus) Pruritus -typically after contact with warm water plethoric appearance - flushed face with purple hue - cyanotic lips erythromyalgia -warmth, pain, erythema, infarction of distal extremities thrombosis -e.g. stroke, MI, PE, DVT, thrombophlebitis haemorrhage -from gums, easy bruising, GI bleeds splenomegaly, hypertension
48
Investigations for Polycythaemia vera
FBC - ↑ Hb/RBC - ↑ haematocrit - ↑ platelets - ↑ WCC - ↓ MCV ``` Jak2 gene mutation (+ve) LDH (↑) erythropoietin (↓) ferritin (often ↓) LFTs ``` NB in secondary causes of polycythaemia there is only an isolated ↑ Hb/RBC and no ↑ platelets
49
Management of Polycythaemia vera
Venesection (1st line) Myelosuppression (2nd line) - e.g. with hydroxyurea or phosphorus-32 - ↑ risk of secondary leukaemia JAK2 inhibitors -e.g. ruxolitinib Aspirin - low dose - to decrease risk of thromboembolic events NB ~5% of pts progress to myelofibrosis or acute leukaemia (↑ risk of this with myelosuppression therapy)
50
Neutropenia
refers ti a low neutrophil count i.e. <1.5x10^9 (normal range (2.0-7.5 x10^9) important to recognise as it predisposes to infection
51
Aetiology of neutropenia
Viral -HIV, EBV, hepatitis Medications: -cytotoxics/chemotherapy, carbimazole, clozapine Benign ethnic neutropenia - seen in black africans, afro-carribbean individuals - no treatment required Haemtological malignacies - aplastic anaemia - myelodysplastic malignancy SLE, RA, haemodialysis
52
Neutropenic sepsis / Febrile neutropenia
oral temp ≥38.5°C / ≥2 consecutive readings ≥38.0°C with a neutrophil count <0.5 x10^9 often associated with cancer therapy
53
Investigations for Neutropenic sepsis / Febrile neutropenia
Only investigate after starting Abx ``` FBC (↓ neutrophils) blood cultures CXR U&Es LFTs ```
54
Presentation of Neutropenic sepsis / Febrile neutropenia
fever tachycardia hypotension recent chemo therapy
55
Thrombocytopenia
a platelets count below the normal range i.e. <150 x10^9/L
56
Aetiology of thrombocytopenia
Most severe - immune thrombocytopenia (ITP) - Disseminated intravascular coagulation (DIC) - thrombotic thrombocytopenic purpura (TTP) - haematological malignancies Others - heparin induced thrombocytopenia (HIT) - HELLP syndrome - Antiphospholipid syndrome - Medication (quinine, aspirin, thiazides, sulphonamides)
57
Pseudo thrombocytopenia
can be caused the use of EDTA as an anticoagulant | has low platelet count but without suggestive symptoms
58
Investigations for thrombocytopenia
``` FBC Blood film coagulation screen U&Es LFTs consider bone marrow biopsy ``` NB rapidly falling platelet count even if within normal range is worrying
59
Management of thrombocytopenia
treat any significant bleeds consult haematology consider replacing platelets -e.g. if anticipated need for urgent surgery, significant bleeding or neurological symptoms NB rapidly falling platelet count even if within normal range is worrying
60
Presentation of thrombocytopenia
epistaxis -usually excessive, prolonged, frequent ``` bleeding gums ↑ bleeding from tooth extractions spontaneous bruising menorrhagia PPH excessive bleeding after surgery ```
61
Immune thrombocytopenia (ITP)
An autoimmune disorder with autoantibodies to platelets causing thrombocytopenia, which may be triggered by viral infections NB in children it is usually acute, following a viral infection or vaccination but is generally self limiting (lasts 1-2 weeks)
62
Presentation of Immune thrombocytopenia (ITP)
often asymptomatic & incidentally picked up on FBC petechiae, bruising, epistaxis absent splenomegaly major haemorrhages e.g. intracranial bleeds are uncommon NB presence of splenomegaly should make you consider other diagnosis
63
Investigations & Management of Immune thrombocytopenia (ITP)
FBC shows platelet count <100 x10^9/L & blood film shows normal platelets 1st line -oral prednisolone if active bleed or urgent need to ↑ platelets use IVIG (human immunoglobulin
64
Investigations & Management of Immune thrombocytopenia (ITP)
FBC shows platelet count <100 x10^9/L & blood film shows normal platelets 1st line -oral prednisolone if active bleed or urgent need to ↑ platelets use IVIG (human immunoglobulin)
65
Thrombotic thrombocytopenic purpura (TTP)
thrombotic microangiopathic where micro thrombi consisting primarily of platelets occlude microvasculature due to deficiency of ADAMTS13 should be treated as an emergency most common in adults usually aged ~40 yrs
66
Investigations for Thrombotic thrombocytopenic purpura (TTP)
FBC - ↓ platelets - ↓ Hb - ↑ reticulocytes - ↓ haptoglobin U&Es - ↑ urea - ↑ creatinine urinalysis -proteinuria ± haematuria Blood film -schisticytes (erythrocyte fragements) LDH (↑↑) direct coombs test (-ve) pretreatment ADAMTS13 activity levels & ADAMTS13
67
Presentation fo Thrombotic thrombocytopenic purpura (TTP)
Fever Fluctuating neurological signs - delirium, altered mental status - stroke, seizures - headache, dizziness Microangiopathic haemolytic anemia - fatigue, dyspnoea, pallor - jaundice, myalgia, arthralgia Impaired renal function: -haematuria, oliguria, proteinuria Purpura -non palpable small purpuric spots or petechiae
68
Direct & indirect Coombs test
Direct -checks if antibodies are stuck to RBC surface In-driect -checks for free antibodies in serum help to rule out haemolytic anaemia
69
Management of Thrombotic thrombocytopenic purpura (TTP)
Plasmaphoresis -IV plasma exchange Steroids -high dose prednisolone Rituximab -if severe NB is treated as an emergency
70
Features of Thrombotic thrombocytopenic purpura (TTP)
Pentad of - fever - fluctuating neurological signs - microangiopathic haemolytic anemia - thrombocytopenia - renal failure
71
Von Willebrand disease (vWD)
The most common hereditary coagulopathy due to the deficiency or abnormal function of von Willebrand factor (vWF) characteristically behaves like a platelet disorder as vWF promotes platelet adhesion & platelet plug formation + vWF binds factor VIII preventing its clearance inherited in an autosomal dominant fashion
72
Von Willebrand disease (vWD)
The most common hereditary coagulopathy due to the deficiency or abnormal function of von Willebrand factor (vWF) characteristically behaves like a platelet disorder as vWF promotes platelet adhesion & platelet plug formation + vWF binds factor VIII preventing its clearance inherited mostly in an autosomal dominant fashion
73
Presentation of Von Willebrand disease (vWD)
often asymptomatic bleeding tendency from mucosa - epistaxis - menorrhagia (common in women) prolonged bleeding from minor injuries / post surgery NB haemoarthrosis are rare
74
Investigations for Von Willebrand disease (vWD)
Coagulation profile - PT (normal) - aPTT (may be ↑) - bleeding time (↑) ``` FBC (normal) Factor VIII (may be ↓) vWF antigen (↓) ristocetin cofactor assay (defective platelet aggregation) ```
75
Management of Von Willebrand disease (vWD)
TXA for mild bleeding Desmopressin (DDAVP) -stimulates vWF release vWF containing factor VIII concentrate -for severe bleeding or surgical prophylaxis
76
Thrombocytosis
a platelets count >450 x10^9/L Aetiology - reactive (platelets = acute phase reactant_ - e.g. stress, surgery, infection - malignancy - e.g. CML - hyposplenism / post splenectomy - essential thrombocytosis
77
Essential thrombocytosis (primary thrombocytosis)
most common myeloproliferative neoplasm due to sustained dysregulates megakaryocytic proliferation, usually seen in pts age 50-60yrs
78
Essential thrombocytosis presentation
commonly asymptomatic erythromelalgia -burning pain & erythema of hands and feet thrombotic events (stroke/TIA/retinal artery occlusion) Vasomotor symptoms -headache, visual disturbance, ocular migraines splenomegaly/hepatomegaly bleeding -primarily GI, simulates duodenal ulcer following duodenal arcade thrombosis
79
Investigations for Essential thrombocytosis
FBC -platelets >600 x10^9 Blood smear -immature precursor cells e.g. myelocytes Bone marrow aspirate - hypercellularity - megakaryocyte hyperplasia LDH (↑) CRP/ESR (normal)
80
Management of Essential thrombocytosis
Hydroxyurea (hydroxycarbamide) -to ↓ platelet count low dose aspirin -↓ thrombotic risk NB Interferon-alpha is preferred in young pts & pregnant women over hydroxyurea
81
Haemophilia
an X-linked recessive inherited bleeding disorder resulting in the deficiency of coagulation factors
82
Genetics of haemophilia
X-linked recessive inheritance hence only seen in males
83
Types of haemophilia
Haemophilia A - deficiency in clotting factor VIII - accounts for ~80% of cases Haemophilia B - deficiency in clotting factor IX - accounts for ~20% of cases Haemophilia C - deficiency of factor XI - very rare - seen in Ashkenazi jews
84
Presentation of haemophilia
repeated haemarthrosis - especially of knees - can lead to haemophilic arthropathy frequent brusing & haematomas oral mucosal bleeding, epistaxis, excessive bleeding after minor procedures musculoskeletal bleeding/haematomas NB female carriers may present with mild symptoms
85
Investigations for haemophilia
Coagulation screen - aPTT ↑ - PT normal - bleeding time normal Factor VIII/IX assay - ↓ / absent joint x-rays -may show degenerative joint disease
86
Management of haemophilia A
prophylactic factor VIII if acute bleeding -FFP/recombinant factor VIII
87
Management of haemophilia B
if acute bleeding - 1st line = recombinant factor IX - 2nd line = PCC or plasma derived factor IX
88
Disseminated intravascular coagulation (DIC)
a syndrome characterised by systemic activation of the coagulation cascade resulting in the formation of intravascular thrombi & the depletion of platelets + coagulation factors
89
Aetiology of Disseminated intravascular coagulation (DIC)
-Sepsis -trauma (trauma induced coagulopathy) -malignancy -obstetric complications (e.g. HELLP syndrome, amniotic fluid embolus) -organ failure (e.g. pancreatitis, fulminant hepatitis) transfusion reaction
90
Presentation of Disseminated intravascular coagulation (DIC)
``` oliguria, hypotension, tachycardia large bruises spontaneous bleeding at venipuncture sites / soft palate / site of trauma massive haemorrhage organ failure -ARDS -PE -purpura fulminans (DIC + extensive skin necrosis) -Waterhouse-Friedirchsen syndrome ```
91
Investigations for Disseminated intravascular coagulation (DIC)
Coagulation screen - PT ↑ - aPTT ↑ - bleeding time ↑ - Fibrinogen ↓ FBC -platelets ↓ D-Dimer ↑
92
Management of Disseminated intravascular coagulation (DIC)
treat underlying cause blood products as needed anticoagulation - if hypercoaguability is the main problem - therapeutic dose LMWH/UFH do not use antifibrinolytics e.g. TXA in pts with DIC
93
Thalassaemia
a group of hereditary haemoglobin disorders characterised by mutations in the alpha or beta global chains inherited in autosomal recessive pattern
94
Alpha-Thalassaemia
deficient production of α-globin | 2 α genes present on each chromosome 16
95
Types of Alpha-Thalassaemia
Normal (α,α / α,α) a+ heterozygous i.e. silent carrier (α,- / α,α) - i.e. one allele affected - borderline Hb & MCV - pt asymptomatic a+ homozygous (α,- / α,- or α,α / -,-) - i.e. two alleles affected - slightly low Hb, slightly low MCV & MCH - pt asymptomatic HbH disease (α,- / -,-) - i.e. three alleles affected - microcytic hypo chromic anaemia - splenomegaly & skeletal deformities α Thalassaemia major / Hb Barts (-,- / -,-) - i.e. all four alleles affected - hydrops fettles & intrauterine death - incompatible with life - Hb Barts = γ chain tetramere
96
Investigations for Alpha-Thalassaemia
FBC - Hb ↓ - MCV ↓ - MCH ↓ - reticulocytes ↑ - RBC count ↑ Iron studies - iron ↑ - ferritin ↑ Blood film + supra vital stain -Heinz bodies (HbH inclusion bodies of β-chain tetrameres)
97
Investigations for Alpha-Thalassaemia
FBC - Hb ↓ - MCV ↓ - MCH ↓ - reticulocytes ↑ - RBC count ↑ Iron studies - iron ↑ - ferritin ↑ Blood film + supra vital stain -Heinz bodies (HbH inclusion bodies of β-chain tetrameres)
98
Management of Alpha-Thalassaemia
no management for silent carriers or asymptomatic pts folic acid supplements for most pts Blood transfusions -especially in HbH disease Splenectomy if hyposplenism Iron chelation -e.g. desferrioxamine to prevent iron overload
99
Beta-Thalassaemia
deficient production of β globes one β global gene on each chromosome 11
100
Types of Beta-Thalassaemia
Normal (β / β) β Thalassaemia trait (β / -) - one functional allele, one non functional - HbA2 >4% - slight anaemia, ↓MCV, ↓MCH - asymptomatic β Thalassaemia major (- / -) - absence of β chains - HbF >90% - severe haemolytic anemia ↓↓MCV, ↓↓MCH - hepatosplenomegaly & skeletal deformities - chronic diffusion dependency - presents in 1st year of life with failure to thrive
101
Investigations for Beta-Thalassaemia
FBC - Hb ↓ - MCV ↓ - MCH ↓ - reticulocytes ↑ Blood film + supra vital stain - Target cells - Teardrop cells Haemoglobin analysis - minimal/no HbA - HbF ↑ - HbA2 ↑ LDH (↑)
102
Management of Beta-Thalassaemia
Repeated transfusions -risk of iron overload iron chelation -e.g. with IV desferrioxamine or PO deferrasirox Folic acid supplements as required consider splenectomy
103
Sickle cell anaemia
Autosomal recessive single gene defect in the β chain of haemoglobin leading to production of sickle haemoglobin (HbS) more common in people of african descent most common form of intrinsic haemolytic anaemia
104
Sickle cell trait
i.e. heterozygous individuals carrying HBSA people with sickle cell trait are generally asymptomatic but may present with gross haematuria due to renal papillary necrosis protective against malaria
105
Presentation of sickle cell disease
symptoms begin age 3-6 months as HbF levels drop pallor, jaundice, lethargy, growth restriction, weakness failure to thrive splenomegaly further presentations with crisis
106
Vaso-occlusive crisis
Most common type of sickle cell crisis due to obstruction of microcirculation by sickle RBCs leading to ischaemia precipitated by cold, infection, dehydration, hypoxia etc. causes severe pain, swollen joints, dactylitis, priapism (in men) may affect major organs e.g. stroke if brain, bowel ischaemia if mesentery, renal papillary necrosis (loin pain &haematuria)
107
Acute chest syndrome
a type of sickle cell crisis essentially a vast-occlusive crisis of the lung vasculature presents with dyspnoea, hypoxia, chest pain, tachypnoea & new infiltrates on CXR symptoms + new infiltrates = diagnostic
108
Aplastic crisis
temporary cessation of erythropoiesis leading to severe anaemia in sickle cell pts usually due to parvovirus B19 infections leads to rapid ↓Hb (~1 week), due to bone marrow suppression the reticulocyte count is ↓ FBC (↓Hb, ↓reticulocytes) requires transfusions
109
Sequestration crisis
mainly seen in babies/young children, sickling in organs e.g. spleen/lungs cause blood pooling and worsening of anaemia presents with splenomegaly, LUQ pain, shock (tachycardia, hypotension) FBC (↓Hb, ↑reticulocytes) NB recurrent spleen sequestration is an indication for splenectomy
110
Hyperhaemolytic crisis
rare sickle cell crisis ↓Hb due to ↑ rate of haemolysis
111
Investigations for sickle cell disease
FBC - Hb ↓ - reticulocytes ↑ (if ↓ indicates aplastic crisis) Blood smear - presence of sickle cells - Howell-Jolly bodies - nucleated RBCs - target cells Haemoglobin electrophoresis - gold standard - no HbA - ~90% HbSS - ~10% HbF U&Es, Lung function tests, LFTs
112
Screening for sickle cell disease
heel prick blood spot test on day 3-10 after birth OR pre-conceptual screening in high risk groups
113
Management of sickle cell disease
Crisis - high dose analgesia e.g. opiates - O2, IV fluids - blood transfusions / exchange transfusion - Abx if signs of infection folic acid supplements oral penicillin prophylaxis from diagnosis unconjugated pneumococcal vaccine from age 2yrs -repeat every 5 years exchange transfusions - as required - should be done if a stroke occurs hydroxycarbamide (hydroxyurea) - to ↑ HbF levels - helps ↓ frequency of crisis NB most pts have crisis plan which includes analgesic regiments, this should be followed, these pts are often deemed to be opiate seeking and left in pain
114
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
most common RBC enzyme defect leading to ↑ susceptibility to oxidative stress X-linked recessive inheritance i.e. male only usually seen in mediterranean & african people generally managed by avoiding triggers for crisis & blood transfusion if necessary
115
Presentation of Glucose-6-phosphate dehydrogenase (G6PD) deficiency
often asymptomatic recurring haemolytic crisis -sudden onset back/abdo pain, jaundice, dark urine, transient splenomegaly, pallor precipitants include fava beans. chlorquine, isoniazid, NSAIDs, sylph-group drugs
116
Investigations for Glucose-6-phosphate dehydrogenase (G6PD) deficiency
FBC - Hb ↓ - reticulocytes ↑ Urinalysis -haemoglobinuria Blood smear -Heinz bodies & bite cells G6PD enzyme assay -3 month after acute episodes ``` Indirect bilirubin (↑) LDH (↑) ```
117
Hereditary spherocytosis
hereditary abnormality of RBCs caused by defects in structural membrane proteins leading to ↓ lifespan of RBCs inherited in autosomal dominant fashion most common cause of hereditary haemolytic anaemia in people of northern european descent
118
Presentation of Hereditary spherocytosis
``` failure to thrive jaundice splenomegaly LUQ pain black pigmented gallstones pallor anaemia ```
119
Investigations for Hereditary spherocytosis
FBC - Hb ↓ - reticulocytes ↑ Blood smear -spherocytes EMA binding test -↓ binding of dye to RBC membranes Unconjugated bilirubin (↑) LDH (↑) direct antiglobulin test (-ve) NB direct antiglobulin test is +ve in other haemolytic anaemias
120
Management of Hereditary spherocytosis
folate replacement splenectomy transfusions if necessary
121
Haemolytic anemia
a group of disorders that result in premature destruction of RBCs leading to a normocytic anaemia Types: - Intrinsic: due to abnormalities in the RBCs - Extrinsic: due to external causes e.g. mechanical damage or immune mediated Mechanism - Intravascular: due to complement fixation, trauma or other extrinsic factors e.g. G6PD/TTP/DIC/ABO mismatch - Extravascular: most common type, RBCs removed by phagocytic system due to intrinsic defects e.g. spherocytosis
122
Aetiology of Haemolytic anemia
Hereditary -G6PD, spherocytosis, sickle cell anaemia Acquired immune: -autoimmune haemolytic anaemia, transfusion reactions, haemolytic disease of the new born, drugs e.g. penicillin Acquired non immune: -DIC, TTP, HUS, malignancy, pre-eclampsia, prosthetic heart valves, paroxysmal nocturnal haemoglobinuria
123
Presentation of Haemolytic anemia
may be sudden with tachycardia, dyspnoea, angina, weakness and mild jaundice gallstones (due to ↑ bilirubin) haematuria (if intravascular)
124
Investigations for Haemolytic anemia
FBC - Hb ↓ - Reticulocytes ↑ - MCV/MCH normal direct antiglobulin test (direct coombs test) - if +ve suggests immune aetiology - if -ve non immune aetiology blood smear - abnormal forms - fragments LDH (↑) haptoglobin (↓) bilirubin (↑) urinalysis (haematuria)
125
Haemolytic uraemia syndrome (HUS)
Triad of AKI, microangiopathic haemolytic anaemia (combs -ve) and thrombocytopenia generally seen in young children, ~90% of cases are due to shiga-toxin producing E.coli (0157:H7) presents with diarrhoea illness preceding onset of thrombocytopenia, microangiopathic haemolytic anaemia and AKI Investigations include Hb ↓, haptoglobin ↓, bilirubin ↑, LDH ↑, reticulocytes ↑, platelets ↓, urea ↑, creatinine ↑ & ↑ schistocytes management is supportive (IV fluids, blood transfusions), with consideration for plasma exchange or eculizumab
126
Aplastic anaemia
a condition defined by pancytopenia with hypo cellular bone marrow and absence of abnormal cells diagnosis requires ≥2 of - Hb <100g/L - platelets <50x10^9 /L - neutrophil count <1.5x10^9 /L
127
Aetiology of Aplastic anaemia
~75% of cases are idiopathic congenital e.g. Flaconi syndrome, drugs e.g. cytotoxics/phenytoin/sulphonamides, radiation, parovirus
128
Presentation of Aplastic anaemia
fatigue, malaise, pallor, dyspnoea ankle oedema purpura, petechiae mucosal bleeding, retinal haemorrhage no lymphadenopathy no hepatosplenomegaly
129
Investigations for Aplastic anaemia
FBC - Hb <100g/L - platelets <50x10^9 /L - neutrophil count <1.5x10^9 /L - reticulocytes ↓ - MCV normal Bone marrow biopsy - hypocellular bone marrow - no abnormal cells
130
Management of Aplastic anaemia
removal of underlying causes e.g. if drug induced haemopoietic stem cell transplant (HSCT) immunsuppression e.g. ATG + ciclosporin supportive care including blood/platelet transfusion
131
Normocytic anaemia
a low level of haemoglobin with a normal MCV Mechanism includes ↓blood volume and/or ↓erythropoiesis
132
Aetiology of Normocytic anaemia
Haemolytic anaemias -sickle cell, HUS, G6PD, hereditary spherocytosis, pyruvate kinase deficiency, TTP, DIC, malaria, mechanical destruction Aplastic anaemia -idiopathic, Falconi syndomre Acute blood loss anaemia of chronic disease anaemia of CKD (falls under anaemia of chronic disease)
133
Aetiology of Normocytic anaemia
Haemolytic anaemias -sickle cell, HUS, G6PD, hereditary spherocytosis, pyruvate kinase deficiency, TTP, DIC, malaria, mechanical destruction Aplastic anaemia -idiopathic, Falconi syndomre Acute blood loss anaemia of chronic disease (most common normocytic anaemia) anaemia of CKD (falls under anaemia of chronic disease)
134
Anaemia of chronic disease
anaemia secondary to chronic inflammation, 2nd most common anaemia overall aetiology include chronic infections e.g. TB, malignancy, inflammatory conditions e.g. RA/SLE Investigations include FBC (normocytic, normochromic anaemia), serum iron (↓), total iron binding capacity (↓), ferritin (↑), reticulocyte count (↓), ESR/CRP (↑) management include treatment of underlying cause, blood transfusion or use of recombinant human erythropoietin/NESP e.g. darbepoetin e.g. in CKD
135
Microcytic anaemia
a condition with ↓Hb & ↓MCV due to insufficient Hb production Aetiology - iron deficiency anaemia (most common) - lead poisoning - late phase anaemia of chronic disease - Thalassaemia - sideroblastic anaemia
136
Iron deficiency anaemia (IDA)
most common type of anaemia due to a deficiency in iron
137
Aetiology of Iron deficiency anaemia (IDA)
excessive blood loss e.g. menorrhagia, GI bleeding dietary inadequacy (e.g. vegans/vegetarians) malabsorption (e.g. coeliac disease, IBD) increased demand (e.g., pregnancy) NB GI bleeding is the most common cause in men & post menopausal women and should prompt consideration of colon cancer
138
Presentation of Iron deficiency anaemia (IDA)
often found incidentally ``` fatigue, SOB on exertion, pallor, palpitations koilonychia (spoon nails) atrophic glossitis angular stomatitis changes in hair / hair loss brittle nails angular chelitis ``` dysphagia due to oesophageal webs (Plummer-Vinson syndrome)
139
Investigations for Iron deficiency anaemia (IDA)
FBC - microcytic hypo chromic anaemia - reticulocytes ↓ iron studies - serum iron ↓ - total iron binding capacity ↑ - transferrin ↑ - transferrin saturation ↓ - ferritin ↓ Blood film - anisopoikilocytosis (red blood cells of different sizes and shapes) - target cells (hypo chromic RBCs) - 'pencil' poikilocytes
140
Management of Iron deficiency anaemia (IDA)
Treat underlying cause PO ferrous sulfate/ferrous salts -side effects include constipation, dark stools, nausea, diarrhoea, abdo pain Parenteral iron supplements are reserved for severe cases Iron rich diet -e.g. dark green leafy veg, meat, iron fortified bread NB consider urgent referral if pt with new IDA age >60yrs or <50yrs presenting with rectal bleeding (?colon cancer)
141
Macrocytic anaemia
a condition with ↓Hb & ↑MCV due to insufficent nucleus maturation reactive to cytoplasmic expansion due ti defective DNA synthesis or defective DNA repair Aetiology - Megaloblastic anaemia (characterised by hyperhsegmented neutrophils) - Vit B12 deficiency - Folate deficiency - normoblastic anaemia - alcohol abuse, liver disease, pregnancy, myelodysplasia, hypothyroidism
142
Pernicious anaemia
autoimmune disorder causing Vit B12 deficiency due to autoantibodies against intrinsic factor* ± gastric parietal cells accounts for ~80% of megaloblastic anaemias NB ↑ risk of gastric cancer
143
Presentation of Pernicious anaemia
fatigue, lethargy, palpitations, faintness, dyspnoea pallor + jaundice (gives lemon twinge) peripheral neuropathy -typical symmetrical affecting arms & legs subacute combined degeneration of the spinal cord - progressive weakness, ataxia, parasthesia - can progress to spasticity, paraplegia neuropsychiatric features -memory loss, poor concentration, confusion, depression, irritability
144
Investigations for Pernicious anaemia
FBC - Hb↓ - MCV↑ Blood smear - hypersegmented neutrophils - megakaryocytes Serum Vit B12 (↓) Folate (normal or ↓) anti intrinsic factor antibodies (+ve) anti parietal cell antibodies (may be +ve)
145
transfusion thresholds
Hb levels <70g/L Hb levels <80g/L in ACS ongoing haemorrhage & chronic anaemia requiring transfusions do not have to meet these thresholds
146
Non haemolytic febrile transfusion reaction
thought to be due to leaked cytokines that accumulate during storage presents with fever, chills and flushing managed with temporarily stopping infusion, paracetamol, restarting transfusion at slower rate with increased monitoring
147
Minor allergic reaction to transfusions
due to foreign plasma proteins presents with urticaria, pruritus (i.e. only cutaneous symptoms) managed by temporarily stopping infusion, antihistamines, restarting transfusion at slower rate with increased monitoring
148
Anaphylactic transfusion reaction
pt presents with SOB, dyspnoea, wheezing, angioedema, hypotension and respiratory distress managed by stopping transfusion, 500mcg adrenaline IM (0.5ml 1:1000) & supportive measures
149
Acute haemolytic transfusion reaction
due to ABO incompatibility (this is a never event) presents within minutes of starting transfusion with fever, abdo pain, hypotension, tachycardia, dyspnoea, chills & flushing management -STOP transfusion, supportive care, fluid resuscitation NB blood should be returned to lab for confirmation i.e. direct coombs test & repeat crossmatch
150
Acute haemolytic transfusion reaction
due to ABO incompatibility (this is a never event) presents within minutes of starting transfusion with fever, abdo pain, hypotension, tachycardia, dyspnoea, chills & flushing can lead to DIC & renal failure management -STOP transfusion, supportive care, fluid resuscitation NB blood should be returned to lab for confirmation i.e. direct coombs test & repeat crossmatch
151
Transfusion associated circulatory overload (TACO)
fluid overload secondary to excessive rate of transfusion or pre-existing HF presents with hypertension, extended JVP S4 heart sound, peripheral oedema, pulmonary oedema (on CXR) and dyspnoea managed by stopping/slowing transfusion & IV diuretics e.g. furosemide
152
Transfusion related acute lung injury (TRALI)
non cardiogenic pulmonary oedema due ↑ vascular permeability secondary to neutrophil activation presents with hypoxia, dyspnoea, hypotension, fever, no signs of fluid overload, SOB & pulmonary infiltrates on CXR managed by stopping transfusion, giving O2 -consider mechanical ventilation if required
153
Delayed transfusion reaction
24h - 28 days post infusion generally mild symptoms including mild fever, jaundice, anaemia, chest/abdo/back pain generally self limiting and do not need treatment
154
Fluid resuscitation
500ml bolus of crystalloids (usually NaCl 0.9%) over 15 min -consider 250ml bolus if elderly or known HF if no response then can repeat boluses to a maximum of 2000ml - juniors should get senior help at 1000ml - ITU support is needed at 2000ml
155
Routine maintenance fluid requirements
Daily requirements over 24h - 25-30ml/kg of fluid - 1mmol/kg of K+/Na+/Cl- - 50-100g of glucose Nb weight based K+ should be rounded to the nearest common fluid available so in 67kg person give 60mmol (one 40mmol & one 20mmol) K+ replacement rate should not exceed 10mmol/h
156
Maximum rate of K+ infusion outside ITU
K+ replacement rate should not exceed 10mmol/h
157
Calculating fluid rate
flow rate = drip factor X (volume (ml)/minutes) drip factor is found on the giving set packaging flow rate is in drops/min`
158
Tumour lysis syndrome
an oncological emergency resulting from the rapid destruction of tumour cells leading to a massive release of intracellular components generally associated with the introduction of combination chemotherapy
159
Tumour lysis syndrome
an oncological emergency resulting from the rapid destruction of tumour cells leading to a massive release of intracellular components generally associated with the introduction of combination chemotherapy associated with high grade lymphomas & leukemias especially Burkitts lymphoma
160
Characteristic features of Tumour lysis syndrome
Hyperkalaemia (K+ ↑) hyperuricaemia (uric acid ↑) hyperphosphataemia (Phosphate ↑) hypocalcaemia (Ca2+ ↓)
161
Presentation of Tumour lysis syndrome
typically within 1-5 days of staring chemo Renal failure -oedema, lethargy, oliguria Hyperkalaemia -arrhythmias (syncope, palpitations, chest pain) nausea, vomiting Hypocalcaemia -seizures, tetany, muscle cramps, perioral paraesthesia
162
Investigations of Tumour lysis syndrome
``` uric acid > 475umol/l or 25% ↑ potassium > 6 mmol/l or 25% ↑ phosphate > 1.125mmol/l or 25% ↑ calcium < 1.75mmol/l or 25% ↓ serum creatinine ≥1.5x upper limit of normal LDH ↑ FBC U&Es ```
163
Management of Tumour lysis syndrome
Prevention is key - High risk pt = IV allopurinol or IV rasburicase + ↑ hydration - low risk pts = PO allopurinol - meds to be given when chemo commences Treatment: - IV fluids & hydration - IV Rasburicase (do not combine with allopurinol as ↓ activity of Rasburicase) - cardiac monitoring - IV calcium gluconate (if symptomatic ↓ Ca2+)
164
Heparin induced thrombocytopenia (HIT)
an immune mediated prothrombotic disorder characterised by a sudden drop in platelet count in a pt receiving heparin containing products due to antibody formation against heparin platelet factor 4 (PF4) usually occurs within 5-10days of initiating heparin NB although platelet levels are low its a prothrombotic condition (platelet levels are low as they are activated & used up)
165
Presentation of Heparin induced thrombocytopenia (HIT)
Thrombotic manifestations - mainly DVT, PE - less commonly acute limb ischaemia, MI, stroke localised skin necrosis at heparin injection sites NB venous thrombosis is more common than retail thrombosis NB bleeding is very uncommon
166
Investigations and management of Heparin induced thrombocytopenia (HIT)
Investigations -FBC (↓platelets >50%) Mangement - stop heparin - address need for ongoing coagulation with argabotran/fondaparinux/danaparoid NB there should be lifetime avoidance of heparin
167
Factor V Leiden
i.e. activated protein C resistance =i most common inherited thrombophilia, affects ~5% of UK population leads to ↑ risk of VTEs, but usually not screened for